semaglutide in kidney disease Ozempic Approved for Diabetic Ozempic picks up FDA indication

Endpoints: NO markers, regulation of vascular flow, parameters of the gut-brain axis in rodent models

Diabetes Management This is a big one

Simple Muscle-Protection Checks Protein consistency : Are you hitting a reasonable protein target most days

Not all patients are candidates for oral therapy

Tirzepatide, but not semaglutide, was capable of reducing aspartate aminotransferase (AST), alanine aminotransferase (ALT) and liver stiffness levels, and it was associated with a significantly higher rate of metabolic dysfunction-associated steatohepatitis (MASH) remission and a decrease of at least one stage of liver fibrosis